Slingshot members are tracking this event:

Ionis Pharmaceuticals earns 2.15M payment, on track for Phase 3 clinical Nusinersen trials

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details IONS earned a  2.15M milestone payment from Biogen (BIIB) for completing enrollment for Phase 3 Nusinersen trials, scheduled to finish by July 2017.  Nusinersen is a Fast Track and Orphan Drug tagged drug designed to combat the effects of Spinal Muscular Atrophy (SMA) by producing a functional SMN protein. record in source
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Spinal Muscular Atrophy, Phase 3 Clinical Trials, Phase 3 Nusinersen Trial, Nusinersen